Compare Abeona Therapeutics Inc (ABEO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Paychex, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Paychex, Inc. trades at $106.25 (market cap $38.44B). The key difference: Paychex, Inc. is far larger — about 103× Abeona Therapeutics Inc's market cap, and Paychex, Inc. pays a 4.4% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PAYX | |
|---|---|---|
Market Cap | $373.32M | $38.44B |
Sector | Health | Industrials |
52-Week High | $7.23 | $147.99 |
52-Week Low | $4.17 | $85.57 |
Enterprise Value | $228.22M | $41.92B |
Dividend Yield | — | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Paychex (PAYX) trades at $108.12, up 1.66% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI suggests mild overbought conditions. Fundamentally, the company maintains robust profitability with 27% net margins and 44.8% ROE, supported by steady revenue growth and strong cash flow generation.
The outlook remains positive with analyst consensus at $110 target and continued AI-driven growth initiatives. However, elevated valuation multiples and potential macroeconomic headwinds to small business hiring present risks. The stock offers a compelling combination of growth execution and shareholder returns through dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
